Health News
Latest health news and updates
Total: 29
When Viral Sympathy Rescued a Hospital: Li Yapeng, Social Media and the Fragility of Chinese Charity
A candid video by Li Yapeng about rent arrears at the Yanran Angel Children’s Hospital triggered a wave of online donations that raised nearly 20 million yuan in days. The surge highlights the power of Chinese social media to mobilise aid quickly but also exposes structural limits: legal separation between fund and hospital, rising urban rents and the need for sustainable funding mechanisms for non‑profit medical providers.
Pumen Tech Wins Approval for DHEA‑S ECL Test as Chinese IVD Firms Broaden Diagnostic Menus
Pumen Technology has received domestic regulatory approval in Guangdong for an electrochemiluminescence DHEA‑S assay, expanding its in‑vitro diagnostic reagent menu. The clearance strengthens the company’s product offering but does not guarantee sales, which will depend on clinical validation, procurement and reimbursement dynamics.
Shenzhen Medtech Firm Wins Approval for DHEA‑S Diagnostic Kit, Signaling Incremental Gains for China's Domestic IVD Sector
Shenzhen Pumen Technology has obtained a Guangdong medical‑device registration certificate for a DHEA‑S diagnostic kit, permitting clinical use in China. The approval reflects steady progress among domestic in vitro diagnostics firms to win regulatory clearances and compete with imported assays in routine endocrinology testing.
China’s Medical Tourism Boom: Clinics, Cash and the New High‑end Travel Trade
China is rapidly developing a commercial medical‑tourism sector that packages clinical care with travel, driven by visa liberalisation, municipal initiatives and public hospitals’ international departments. The market offers low prices and fast access, but long‑term success depends on international accreditation, patient safety standards and managing domestic equity concerns.
Recordati’s China Exit Leaves Cushing’s Patients Stranded and Exposes Fragile Market for Rare‑Disease Drugs
Recordati’s Chinese subsidiary has filed to deregister, ending supply of osilodrostat — the only oral drug for Cushing’s syndrome on the Chinese market — less than a year after its commercial launch. The withdrawal highlights structural problems in China’s rare‑disease market: high prices, thin sales, uncertain reimbursement and weak incentives for suppliers, all of which risk interrupting care for vulnerable patients.